Is CRISPR Therapeutics (CRSP) Pricing Look Attractive After Recent Share Price Weakness
- If you are trying to figure out whether CRISPR Therapeutics is attractively priced or not, the recent share performance gives you a lot to think about.
- The stock last closed at US$45.75, with a 1.1% decline over 7 days, a 23.9% decline over 30 days, a 14.9% decline year to date, but a 23.7% gain over 1 year and a 1.1% gain over 3 years compared to a 61.7% decline over 5 years.
- These shifts in returns have kept CRISPR Therapeutics on many watchlists, as investors weigh shorter term weakness against longer term moves. Recent coverage has focused on how sentiment toward gene editing and related therapies can influence interest in the stock, which helps explain why price swings can be sharp even without company specific headlines.
- On…
Source link
